Standard Biotools (LAB) Net Equity Issued and Repurchased (2017 - 2022)

Standard Biotools (LAB) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $202.7 million in Q2 2022.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $202.7 million in Q2 2022; TTM through Sep 2023 was $202.7 million, a 0.0% change from a year earlier, with the FY2022 full-year figure at $225.0 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q2 2022 stood at $202.7 million, up from $20.1 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for LAB reached as high as $202.7 million in Q2 2022 and fell as low as $20.1 million in Q3 2020.
• Historically, Net Equity Issued and Repurchased has averaged $103.8 million across 4 years, with a median of $96.1 million in 2018.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 117914.0% in 2018 and fell as far as 117914.0% in 2018.
• Year by year, Net Equity Issued and Repurchased stood at $58.9 million in 2018, then surged by 126.29% to $133.3 million in 2019, then plunged by 84.92% to $20.1 million in 2020, then soared by 908.46% to $202.7 million in 2022.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $202.7 million in Q2 2022, $20.1 million in Q3 2020, and $133.3 million in Q1 2019.